Select Medical (SLMC) Names Dr. Samuel Hammerman Chief Medical Officer of its Long-Term Acute Care Hospital Division

Select Medical (SLMC) Names Dr. Samuel Hammerman Chief Medical Officer of its Long-Term Acute Care Hospital Division

MECHANICSBURG, Pa., Jan. 7, 2013 -- Select Medical today announced that Samuel Hammerman, M.D., MMM, FCCP, has been named Chief Medical Officer for the company's division of 110 long-term acute care (LTAC) hospitals. The LTAC hospitals operate as Select Specialty or Regency hospitals. Having previously served as medical director for two Select Specialty hospitals in Pennsylvania, as well as on the company's National Medical Advisory Board, Dr. Hammerman is familiar with Select Medical's operations and clinical protocols.

In his new leadership position, Dr. Hammerman will oversee and supervise the LTAC hospital division's medical practice, working closely with the medical and clinical leadership teams at the local, regional and national levels. His position is new and marks a milestone in the continuing growth and success of Select Medical's LTAC division.

"Dr. Hammerman will collaborate with our medical staff and clinical leadership to further establish our evidencebased practice guidelines and protocols, all with a special focus on the care of Chronically Critically Ill (CCI) patients," said Joe Gordon, FACHE, President of Select Medical's LTAC hospital division. "We welcome and congratulate Dr. Hammerman on his appointment as our full-time Chief Medical Officer. Ultimately, our patients will benefit most from his leadership and guidance."

With an extensive background in pulmonology and critical care medicine, Dr. Hammerman is well suited to provide medical leadership for Select Medical's critically ill patients, many of them on mechanical ventilators. Dr. Hammerman most recently served as director of pulmonary and critical care medicine for Geisinger Health System. At Geisinger Wyoming Valley Hospital, he led innovation initiatives focusing on patientcentered clinical care, operations, quality and safety, and education. He was also previously employed by the University of Pittsburgh Medical Center and its Magee Women's Hospital. Earlier in his career, he was in private practice in Pennsylvania and Maryland, specializing in pulmonary and critical care medicine.

A frequent lecturer and published author, Dr. Hammerman is a member of the American College of Physician Executives and the Society of Critical Care Medicine. He also serves as governor (Commonwealth of Pennsylvania) of the American College of Chest Physicians. He currently serves as an adjunct clinical assistant professor at Temple University School of Medicine and Philadelphia College of Osteopathic Medicine.

Dr. Hammerman is a graduate of the Medical University of South Carolina and completed a postdoctoral fellowship in pulmonary and critical care medicine at Boston University Medical Center. He earned his master's degree in medical management (MMM) from Carnegie Mellon University and his bachelor's degree from the University of Maryland. He will continue to serve as a member of Select Medical's National Medical Advisory Board, where he will collaborate with Dr. David Jarvis, the LTAC hospital division's National Medical Director.

About Select Medical
Select Medical helps improve quality of life for approximately 30,000 patients in a typical day, making it one of the nation's largest providers of specialized acute and post-acute care. Select Medical's network of 30,000 employees operate or support 110 hospitals specializing in long-term acute care, 12 medical rehabilitation hospitals, and approximately 965 outpatient clinics offering physical and occupational therapy. Select Medical also provides contract therapy services at more than 500 sites and physical therapy and/or athletic training to approximately 300 high schools, colleges, and professional teams nationwide. For more information, visit

SOURCE Select Medical

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.